Some updates from our team at @thecollectiv3e - we've been growing fast!
1. We're opening our NYC HQ in Chelsea.
A 6,000 sqft loft in the heart of the city. This will be the premier space for founders and builders in New York. There are very few good coworking spaces in NYC - we want to change that.
We're designing our space to be the best place for founders and builders in the city. We'll have private offices, a maker-space, a content room, a kitchen, a lounge, and much more.
2. We launched our talent arm.
From the beginning, we've specialized in finding exceptional people and bringing them together. For a long time that meant events and community. Now we're applying the same approach to hiring.
We believe great hires come from in-person relationships and a deeply trusted network. We're excited that @clairajv recently joined us as our Founding Head of Talent. She'll be helping members find the right people to supercharge their teams.
3. The community & team is growing quickly!
Our latest group, Cohort 4, filled up in 3 weeks (our fastest ever) and we received over 450+ applications during that time period. We recently launched in LA and are happy to see the community coming together nicely.
We're also pumped to welcome new fellows to the team across SF, NYC, and LA - @mikashimmura, @maxlovestweets, @Rick_Yang2, @jaydenxxia, @allixzheng, @Davexyao, @l1frances, @ssarahfann, and @BoitDarley.
We've come a long way in 12 months, but it feels like we're just getting started.
Massive shoutout to all of our members, our partners, and everyone who has supported us so far!
Introducing our fellows at The Collective!
We're excited to welcome new faces across NYC, SF & LA and to congratulate our new city leads, @risashimmura, @k2briian, @FinnStaeblein, @olivialiu82, and Nick.
New York:
Rick: Harvard, Picus Capital
@miraya_j: UIUC, Dorm Room Fund
@sidr29: Columbia, founder Stealth
@TanejaPriyal: McMaster, MoTS E3 Group
@dingdongtinz: Columbia, Dorm Room Fund
@mikashimmura: Parsons, Cartier, ex-Hermès
@tinajyao: UVA, Girls Who Innovate, content creator
@michelletliu: UCLA, sundays in la, 8VC, Figma, Apple
@ichristinew: Boston College, content creator (267k+)
San Francisco:
@allixzheng: Cornell, Uber
@Davexyao: UC Berkeley, Blackstone
Jayden: UCSD, Product at Solace, Lawnly
@maxlovestweets: UC Berkeley, Centerview
@lindictive: NYU, ex-founder, Growth at Scope
@createdbymason: UC Berkeley, Hackathon Company of California
Los Angeles:
@Sarah___Fan: USC, GTM Lemma, ex-Photon
@ssarahfann: USC, ex-SpaceX, Anduril, 8VC
@boitdarley: Harvard, The TerraCotta Group
Frances: USC, Permanent Capital Ventures
@thecollectiv3e exists to build spaces for ambitious young people changing the world. This is the strongest group we've ever brought together, and we can't wait to see what they do next.
Congrats to each one of them!
I don't think anyone is looking to 10x their check at $10b. Moreso it is probably seen as:
1) an opportunity to deploy a large number of absolute dollars
2) make 40% IRR via a 2x+ bump (not 10x) on the next round in under 2 years cc Etched, Instinct etc
$1B on 10B pre-revenue round math:
10-yr hold, 5% employee dilution a year + 50% from funding.
GP retains ~30% of initial ownership.
To make 10x on the check, the company is worth ~$334B, not $100B.
10x gross becomes ~6x net to the LP.
So, inside 10 years, you are building Databricks + Ramp, OpenAI or Anthropic.
If you are suggesting that we cut off American vc then you are also suggesting that Chinese biotechs should instead license P2 rdy assets to European sponsors. Such a regime would also support profits from Chinese innovation flowing out of US (more layoffs) to European pharma
Biotech VCs going to China will see this and feel nothing for the employees and their families affected
They’ll say it’s about cures while they fund a me-three
Given that biology is a lot harder to monetize at the scale that venture demands, it selects for founders who are building for reasons other than raising lots of money.
I did my 5th deal in bio last week, and I suspect I will be doing much more of it going forward
as a non-traditional bio investor, how I got here:
> organically met founders using technologies I have a track record of investing in (e.g. robotics, AI), but applied to bio problem spaces
> founders doing this seemed stand-out smart, so decided to explore whether this hypothesis of extremely smart founders building in bio is correct (by meeting more across the board)
> confirm hypothesis + majority of the most insane pitches I've heard in the last 6 months were from bio founders. tl;dr weird, highly impactful (and probably undervalued) is abundant in bio
what I'm currently most interested in (largely moving upstream to the molecular level of themes I've already been investing in):
> new molecules (e.g. material sciences or industrial bio). largely upstream from the fund's main thematic focus of investing in physical tech (e.g. new computing surfaces) on a molecular level i.e. manipulating atoms
> lab automation (basically a nexus with existing investing in robotics etc, though idk how many bets there are to make here)
> "superman" thesis i.e. moonshots that enable superhuman care for or capabilities in the human body (my last investment was here). a molecular evolution of investing in tech that augments human capability
(I assume these interest areas will evolve quickly)
Meet Context, the first AI office suite.
Humanity spends 2.5 trillion hours a year on office work. Context can one-shot most of it.
Welcome to the era of vibe-working.
Sign up today or tag @contextsuite with a prompt.